血塞通注射液治疗急性出血性脑血管病的临床疗效

Clinical Efficacy of Xuesaitong Injection for the Treatment of Acute Hemorrhagic Cerebrovascular Disease

目的探讨血塞通注射液治疗急性出血性脑血管病的临床疗效。方法从该院2010年10月—2013年10月收治的急性出血性脑血管病患者中随机选择100例进行研究,随机分为两组,并别给予血塞通注射液治疗和常规治疗。结果观察组不良反应发生率为2.0%,对照组为14.0%。经比较,差异无统计学意义(P>0.05);观察组的最终总有效率为96.0%,对照组为78.0%,经比较,差异有统计学意义(P<0.05)。结论血塞通注射液治疗急性出血性脑血管病,不良反应较少,疗效确切,值得推广。

Objective To investigate the clinical efficacy of Xuesaitong Injection in the treatment of acute hemorrhagic cerebrovascular disease. Methods 110 cases of patients with acute hemorrhagic cerebrovascular disease admitted in our hospital from October, 2010 to October, 2013 were randomly selected for the study and divided into two groups treated with Xuesaitong Injection therapy and routine therapy, respectively. Results The incidence of adverse reactions of the observation group was 2.0%, and that of the control group was 14.0%, the difference was not statistically significant by comparison （P〉0.05）. The final total effective rate of the observation group was 96.0%, and that of the control group was 78.0%, the difference was statistically significant by comparison（P〈0.05）. Conclusion For acute hemorrhagic cerebrovascular disease, the curative effect of Xuesaitong Injection is definite with less adverse reactions, which is worthy of promotion.